Aura Biosciences, Inc. Stock-Based Compensation
Aura Biosciences, Inc. (AURA) reported Stock-Based Compensation of $16.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Aura Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $12.37M, a 222.67% increase year-over-year.
- Aura Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.82M, a 8.82% increase year-over-year.
- Aura Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.28M, a 11.75% increase year-over-year.
- Aura Biosciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.69M, a 34.11% increase year-over-year.
- Aura Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $14.32M, a 22.14% increase from fiscal 2024.
- Aura Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $11.72M, a 33.63% increase from fiscal 2023.
- Aura Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $8.77M, a 36.81% increase from fiscal 2022.
- Aura Biosciences, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $6.41M, a 177.94% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $16.19M 10-Q · filed 2026-08-11 | $19.47M derived: sum of 3 quarters · filed 2026-08-11 | $23.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.82M 10-Q · filed 2026-05-11 | $7.11M derived: sum of 2 quarters · filed 2026-05-11 | $10.79M derived: sum of 3 quarters · filed 2026-05-11 | $14.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.97M derived: sum of 2 quarters · filed 2026-03-30 | $10.80M derived: sum of 3 quarters · filed 2026-08-11 | $14.32M 10-K · filed 2026-03-30 |
| 2025-09-30 | $3.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $7.52M derived: sum of 2 quarters · filed 2026-08-11 | $11.04M 10-Q · filed 2025-11-13 | $13.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $7.35M 10-Q · filed 2026-08-11 | $10.28M derived: sum of 3 quarters · filed 2026-08-11 | $13.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.51M 10-Q · filed 2026-05-11 | $6.45M derived: sum of 2 quarters · filed 2026-05-11 | $9.20M derived: sum of 3 quarters · filed 2026-05-11 | $12.33M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.69M derived: sum of 2 quarters · filed 2026-03-30 | $8.81M derived: sum of 3 quarters · filed 2026-03-30 | $11.72M 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.88M derived: sum of 2 quarters · filed 2025-11-13 | $8.79M 10-Q · filed 2025-11-13 | $11.39M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $6.04M 10-Q · filed 2025-08-13 | $8.64M derived: sum of 3 quarters · filed 2025-08-13 | $10.96M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $2.91M 10-Q · filed 2025-05-15 | $5.51M derived: sum of 2 quarters · filed 2025-05-15 | $7.84M derived: sum of 3 quarters · filed 2025-05-15 | $9.77M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $4.93M derived: sum of 2 quarters · filed 2025-03-24 | $6.86M derived: sum of 3 quarters · filed 2025-03-24 | $8.77M 10-K · filed 2025-03-24 |
| 2023-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.26M derived: sum of 2 quarters · filed 2024-11-12 | $6.17M 10-Q · filed 2024-11-12 | $7.98M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.84M 10-Q · filed 2024-08-08 | $5.66M derived: sum of 3 quarters · filed 2024-08-08 | $7.38M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.91M 10-Q · filed 2024-05-09 | $3.73M derived: sum of 2 quarters · filed 2024-05-09 | $5.44M derived: sum of 3 quarters · filed 2024-05-09 | $6.73M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $3.53M derived: sum of 2 quarters · filed 2024-03-27 | $4.82M derived: sum of 3 quarters · filed 2024-03-27 | $6.41M 10-K · filed 2024-03-27 |
| 2022-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.00M derived: sum of 2 quarters · filed 2023-11-09 | $4.60M 10-Q · filed 2023-11-09 | $5.89M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.88M 10-Q · filed 2023-08-09 | $4.18M derived: sum of 3 quarters · filed 2023-08-09 | $4.73M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.59M 10-Q · filed 2023-05-11 | $2.89M derived: sum of 2 quarters · filed 2023-05-11 | $3.44M derived: sum of 3 quarters · filed 2023-05-11 | $3.72M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.85M derived: sum of 2 quarters · filed 2023-03-15 | $2.12M derived: sum of 3 quarters · filed 2023-03-15 | $2.31M 10-K · filed 2023-03-15 |
| 2021-09-30 | $554.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $825.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.01M 10-Q · filed 2022-11-10 | $1.19M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $456.00K 10-Q · filed 2022-08-11 | $635.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $185.00K 10-Q · filed 2022-05-12 | $364.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $736.00K 10-K · filed 2022-03-23 | ||
| 2020-09-30 | $557.00K 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |